Seattle Genetics, Inc. Reports Fourth Quarter and Year 2014 Financial Results

Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the fourth quarter and year ended December 31, 2014. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development accomplishments, progress with other proprietary pipeline programs and antibody-drug conjugate (ADC) collaborator updates. In addition, Seattle Genetics outlined anticipated 2015 activities and financial outlook.

Help employers find you! Check out all the jobs and post your resume.